secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108447
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VivoSim Labs appoints Tony Lialin as Chief Commercial Officer
-------------------------------------------------------------

- Tony Lialin appointed CCO effective Aug 11, 2025; leads go-to-market strategy for NAMkind liver/intestine 3D models.
- Annual salary $360,000, sign-on bonus $10,000, target bonus up to 40% of base salary.
- Granted option to purchase 40,000 shares vesting over 4 years (25% cliff at 1 yr, then quarterly).
- Company cites global liver/GI in-vitro market at $641M in 2024, U.S. share 50.8% ($325M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/0000950170-25-108447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/vivs-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer